NN7008-3553 A Multi-centre Non-interventional Study of Safety and Efficacy of turoctocog alfa (rFVIII) during Long-Term Treatment of Severe and Moderately Severe Haemophilia A (FVIII ≤2%) (guardian™ 5)First published 10/01/2014 Last updated 22/02/2024 EU PAS number: EUPAS5501StudyFinalised
Clinical Reporting Anchor and Disclosure (1452) Novo Nordisk A/S pactadmin@novonordisk.comStudy contactpactadmin@novonordisk.com